AB
☆    

India,
2013-01-10 09:42
(4919 d 04:52 ago)

Posting: # 9811
Views: 4,247
 

 Scaling approach in steady state [Design Issues]

Dear All,

Can we adopt a ref scaling approach in a steady state design for highly variable drugs?
if yes, in such cases what are the parameters to consider for the scaling for USFDA & EMA submission studies.

Many thanks in advance.

Regards,
AB
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-01-10 14:30
(4919 d 00:04 ago)

@ AB
Posting: # 9814
Views: 3,649
 

 Scaling approach in steady state

Dear AB,

❝ Can we adopt a ref scaling approach in a steady state design for highly variable drugs?


Why not?

❝ if yes, in such cases what are the parameters to consider for the scaling for USFDA & EMA submission studies.


Not sure what you mean by “parameters to consider for the scaling”.
  • PK metrics in steady state are AUCτ and Cmax,ss.
  • FDA: RSABE acceptable for AUC and/or Cmax if sWR ≥0.294.
    GMR within 0.8–1.25. Minimum sample size 24 (rumor!).
  • EMA: ABEL acceptable only for Cmax if CVWR >30%; maximum scaling factor limited to 50%.
    GMR within 0.8–1.25. Clinical justification required.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
AB
☆    

India,
2013-01-11 14:42
(4917 d 23:52 ago)

@ Helmut
Posting: # 9825
Views: 3,418
 

 Scaling approach in steady state

Dear Helmut,

Many thanks for your response.
“parameters to consider for the scaling”.
I mean which PK parameters to consider for the scaling.
Along with PK parameters and criteria you mentioned, should we also consider Cmin for scaling or not?
am not sure to what extent my question is valid.

Thanks again

Regards,
AB
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-01-11 15:11
(4917 d 23:23 ago)

@ AB
Posting: # 9826
Views: 3,491
 

 Only AUCt and Cmin

Dear AB!

❝ Along with PK parameters and criteria you mentioned, should we also consider Cmin for scaling or not?


According to the [image] guidance you should report Cmin together with Cav, degree of fluctuation [(Cmax–Cmin)/Cav], and swing [(Cmax–Cmin)/Cmin]. A statistical comparison is not required.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
328 visitors (0 registered, 328 guests [including 12 identified bots]).
Forum time: 15:35 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5